Drug intelligence / Profile preview

RT304

Development stage: Preclinical
Lead developer: Revio Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

RT304 is a pharmaceutical program under development by Revio Therapeutics, focused on the reformulation of a proven drug into an oral solution for oncology applications. As part of Revio's 'Reformulation Programs' (RT301-RT308), RT304 aims to enhance the delivery and efficacy of an existing therapeutic agent. While the specific active pharmaceutical ingredient and its molecular target remain undisclosed by the developer, the program is currently in the preclinical or early clinical bridging stage, targeting improvements in patient outcomes through optimized formulation.

Beyond the preview

Go deeper on RT304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT304.

Explore the full profile